Uncategorized

Two Stocks in Concentration: TransCanada Corporation (NYSE:TRP) & Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)

TransCanada Corporation (NYSE:TRP)

TransCanada is a North American energy company. They are focused on natural gas transmission and power services. Their pipeline transports the majority of Western Canada’s natural gas production to growing markets in Canada and the United States.

TransCanada Corporation (NYSE:TRP)’s Financial Overview

TransCanada Corporation (NYSE) surged 1.68% yesterday to close its trading session at $41.76. The company has 1 year Price Target of $54.51. TransCanada Corporation has 52-Week high of $46.19 and 52-Week Low of $34.58. The stock touched its 52-Week High on 46.19 and 52-Week Low on 34.58. The stock traded with the volume of 1.41 Million shares yesterday. The firm shows the market capitalization of $38.79 Billion.

TransCanada Corporation (NYSE) reported its last quarterly earnings on 12/30/2017 where the firm reported its Actual EPS of $0.65/share against the analyst consensus estimate of $0.62/share. The difference between the actual and expected EPS is $0.03 a share with a surprise factor of 4.8%.

The firm is trading with SMA20 of -0.02 Percent, SMA50 of 4.25 Percent and SMA200 of 0.38 percent. TransCanada Corporation has P/S value of 3.86 while its P/B value stands at 2.1. Similarly, the company has Return on Assets of 3.7 percent, Return on Equity of 14.6 percent and Return on Investment of 4 Percent. The company shows Gross Margin and Operating Margin of 59.5 percent and 29.6 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 1.7 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 19 analysts offering 12-month price forecasts for TransCanada Corp have a median target of 48.59, with a high estimate of 55.85 and a low estimate of 33.17. The median estimate represents a +16.35% increase from the last price of 41.76.

TransCanada Corporation is expected* to report earnings on 02/14/2019 after market close. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.7. The reported EPS for the same quarter last year was $0.65.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)’s Financial Outlook

The 2 analysts offering 12-month price forecasts for Pieris Pharmaceuticals Inc have a median target of 7.50, with a high estimate of 10.00 and a low estimate of 5.00. The median estimate represents a +149.17% increase from the last price of 3.01.

Pieris Pharmaceuticals, Inc. is estimated to report earnings on 03/08/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.16. The reported EPS for the same quarter last year was $0.17.

According to Zacks Investment Research, Pieris Pharmaceuticals, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock declined -0.66% and closed its last trading session at $3.01. The company has the market capitalization of $162.81 Million. The stock has 52-week high of $9.75 and 52-Week low of $2.39. The firm touched its 52-Week high on 9.75 and 52-Week low on 2.39. The company has volume of 335541 shares. The company has a total of 54.09 Million shares outstanding.

Pieris Pharmaceuticals, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.11/share where the analyst estimated EPS was $-0.12/share. The difference between the actual and Estimated EPS is $0.01. This shows a surprise factor of 8.3 percent.

The company has YTD performance of 13.16 percent. Beta for Pieris Pharmaceuticals, Inc. stands at 1.86 while its ATR (average true range) is 0.2. The company has Weekly Volatility of 5.97%% and Monthly Volatility of 6.90%%.

Pieris Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of 9.16%, Distance from 50-Day Simple Moving Average of 3.51 percent and Distance from 200-Day Simple Moving Average of -35.11%.

The Company currently has ROA (Return on Assets) of -5.1 percent, Return on Equity (ROE) of -18.1 Percent and Return on Investment (ROI) of -136.5% with Gross margin of 0 percent and Operating & Profit margin of -27.5% and -17.9% respectively.